Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that inhibits platelet activation and aggregation.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** In patients with a history of myocardial infarction (MI), ticagrelor is indicated to reduce the rate of cardiovascular (CV) death, MI, stroke, and all-cause mortality.
* **Stable Coronary Artery Disease (CAD):** In patients with stable CAD with a history of MI, ticagrelor is indicated to reduce the rate of CV death, MI, and stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **Duration:** Typically continued for at least 12 months. Duration may be extended based on individual patient risk assessment and in consultation with a cardiologist.
* **Stable CAD (with history of MI):**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
* There is no established use of ticagrelor in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended.
* **Hepatic Impairment:** No dose adjustment is recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to limited data.
## Contraindications
* Hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding.
* History of intracranial hemorrhage.
## Adverse Effects
* **Most Common:** Bleeding (including fatal and life-threatening), dyspnea, bradycardia, increased serum creatinine, ventricular pauses.
* **Serious:** Major bleeding, anaphylaxis, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor concentrations.
* **Other Antiplatelet Agents/Anticoagulants:** Increased risk of bleeding. Use with caution and monitor for signs of bleeding.
* **Proton Pump Inhibitors (PPIs):** Some studies suggest that concomitant use of PPIs may reduce ticagrelor exposure and efficacy. The clinical significance is uncertain. Separation of dosing time may be considered.
* **Atorvastatin:** Concomitant use can lead to increased exposure to atorvastatin; monitor for statin-related adverse effects.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding (e.g., bruising, hematuria, melena, epistaxis).
* **Heart Rate:** Assess for bradycardia, especially in patients with risk factors for bradycardia.
* **Renal Function:** Monitor serum creatinine.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, which may allow for faster platelet function recovery compared to clopidogrel if surgery is required.
* Dyspnea is a common side effect and is usually mild and transient, but should be evaluated to rule out other causes.
* If a dose of ticagrelor is missed, the patient should take the next dose at the scheduled time. They should not double the dose.
* Maintenance dose for stable CAD is 60 mg twice daily. The 90 mg twice daily dose is reserved for ACS.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and management may vary based on individual patient factors and local protocols.*
